← Patent-cliff monitor Loss of exclusivity November 2041 latest FDA-listed patent expiry
Company ALKERMES INC
Drug detail Brand name LYBALVI Active ingredient OLANZAPINE; SAMIDORPHAN L-MALATE Strength 5MG;EQ 10MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2021 Marketing status RX
Listed patents Patent Expires Type 11951111 November 2041 use U-3887 11707466 November 2041 product 12390474 November 2041 product 10300054 May 2033 product 8778960 February 2032 use U-3137 9119848 August 2031 substance 11241425 August 2031 use U-3137 10716785 August 2031 use U-3137 9517235 August 2031 use U-3138 12194035 August 2031 use U-3141 11185541 August 2031 use U-3140 11793805 August 2031 use U-3734 11351166 August 2031 use U-3141 9126977 August 2031 product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.